Analysis of the key themes driving M&A activity reveals that regenerative medicine accounted for six pharmaceutical deals announced in Q3 2024, worth a total value of $27m. The $25m acquisition of UniQure by Genezen Laboratories was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
Smarter leaders trust GlobalData
In value terms, regenerative medicine-related deal activity remained flat in Q3 2024 compared with the previous quarter and as compared to Q3 2023. Related deal volume increased by 500% in Q3 2024 versus the previous quarter and was 40% lower than in Q3 2023.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
